Regulatory Momentum SUPPORT II pivotal trial and FDA approval to initiate create near-term demand opportunities among interventional cardiology and cardiac ICU departments; target early adopters at centers participating in or watching pivotal trials; leverage clinical evidence generation to drive procurement discussions.

Competitive Positioning Position Supira as a catheter-based alternative in pVAD market competing with Abiomed/J&J; emphasize next-generation design, potential for easier deployment and patient outcomes; approach hospitals evaluating pVAD options with clear value propositions and favorable pricing.

Funding Backing Significant Series E funding led by Novo Holdings signals growth trajectory and financial stability; use this as a credibility lever with procurement, health systems, and distributors; align sales cycles with expected ramp in manufacturing and clinical adoption.

Market Focus Primary market includes high-risk patients undergoing interventional procedures experiencing cardiogenic shock; focus sales efforts on interventional cardiology labs, cath labs, cardiac ICU, and hospital purchasing teams; develop investigator-led case studies, site contracts, and payer discussions.

Leadership Credibility Recent board additions bring strategic credibility and access to hospital networks; leverage introductions and advisory support to reach key decision-makers, clinical champions, and potential partners in health systems.